# Zoetis: Quality Animal-Health Franchise Trading Near a 52-Week Low, With a Same-Day FDA Nod

Zoetis (ZTS), In the Sweet Spot pick for August 14, 2026: Zoetis screens with 94.2 quality and an 18.4% PAR near the top of our sweet spot, but a tough stret...

Canonical: https://www.manifestinvesting.com/sweet-spot/zts-zoetis-2026-08-14

In the Sweet Spot · August 14, 2026 · Zoetis (ZTS) · Healthcare

**Zoetis screens with 94.2 quality and an 18.4% PAR near the top of our sweet spot, but a tough stretch of earnings calls and a fresh FDA emergency authorization make today worth a closer look.**

Zoetis (ZTS) was Manifest Investing's In the Sweet Spot daily stock pick for August 14, 2026. At the time of the pick, Zoetis carried a quality percentile of 94 and a projected annual return (PAR) of 18.4% against a MIPAR of 8.7%, placing it inside the sweet spot of 13.7% to 18.7%.

## Key metrics at the time of the pick

- **Quality percentile**: 94
- **Projected annual return (PAR)**: 18.4%
- **MIPAR (median PAR of coverage)**: 8.7%
- **PROVE**: 12.8%
- **Core score (of 300)**: 283
- **Financial strength (of 100)**: 91
- **EPS stability (of 100)**: 97.2
- **Sales growth forecast**: 5.3%
- **P/E ratio**: 17.5
- **Price at pick**: $75.41
- **52-week low**: $71.45
- **52-week high**: $160.48
- **Above 52-week low**: 5.5%
- **Below 52-week high**: 53.0%
- **Dividend yield**: 2.6%
- **Projected yield**: 1.7%
- **In the sweet spot**: Yes
- **Triple play**: No

## Why Zoetis, why today

Zoetis (ZTS) sits at $75.41, just 5.5% above its 52-week low of $71.45 and roughly 53% below its 52-week high of $160.48. That combination of a beaten-down price and a still-excellent underlying business is exactly the kind of tension we like to dig into in this feature.

The immediate news hook: on August 13, the FDA granted Zoetis’s Simparica Trio an emergency use authorization for treating New World screwworm infestations in dogs and puppies, per Businesswire and Reuters coverage. It’s a small, specific development, but it lands the same week the stock touched a fresh 52-week low following a price-target cut from Piper Sandler (per Defenseworld.net), so the stock has had two very different kinds of news in a matter of days.

## What our methodology shows

Zoetis carries a quality percentile of 94.2, meaning it ranks in the top 6% of all the stocks we cover on financial strength, EPS stability, and relative sales growth and profitability. Underneath that, financial strength is a strong 91.4 (out of 100) and EPS stability is 97.2 (out of 100), reflecting a long history of consistent earnings. Add those two figures to the 94.2 quality percentile and you get a core score of 283 out of a possible 300, comfortably above the 225 threshold we associate with core-holding candidates.

On return expectations, Zoetis’s projected annual return (PAR) is 18.4%, which sits near the top of our sweet spot, the band running from MIPAR (currently 8.7%) plus 5 to plus 10 percentage points, or 13.7% to 18.7%. A PAR this high after a large price decline is consistent with the methodology: as the price falls and the underlying growth and profitability assumptions hold, projected return rises. The stock’s growth forecast is a modest 5.3%, and it trades at a P/E of 17.5, with a current dividend yield of 2.65% versus a projected yield of 1.7%.

## The honest complication

We’d be doing readers a disservice if we didn’t flag what’s driving that depressed price. Our AI review of Zoetis’s recent earnings calls, covering Q4 2025 through Q2 2026, found a business under real pressure. Management cut full-year guidance twice in six months as U.S. Companion Animal sales turned negative and the key Dermatology franchise saw a new competitor enter the market. That same review also credited two real bright spots: Livestock and Companion Animal Diagnostics have both posted consistent double-digit growth across the same stretch, providing ballast while the U.S. pet-care business works through a rough patch. Leadership changes announced alongside the Q2 report, including a new CFO/COO starting August 17, add a layer of execution risk to watch during the recovery.

Zoetis’s next earnings date is November 3, 2026, roughly three months out, giving investors a window to watch whether the gross-to-net pricing investments management has deployed start to show up in stabilized market share before then.

## The takeaway for research

This is a name where a high quality score and a sweet-spot PAR coexist with a genuinely challenged near-term operating picture. That’s not a contradiction in our methodology, it’s the methodology doing its job: pricing in the uncertainty via a lower stock price and, mechanically, a higher projected return. Whether the animal-health franchise’s competitive and macro pressures prove temporary or more structural is exactly the kind of question worth studying further, not a conclusion we’re drawing for you.

_This is educational research content, not a recommendation to buy or sell. Always consider your own goals, risk tolerance, and further due diligence._

## Sources

- [Zoetis Receives Emergency Use Authorization for Simparica Trio for Treatment of New World Screwworm Infestations in Dogs and Puppies](https://www.businesswire.com/news/home/20260813903513/en/Zoetis-Receives-Emergency-Use-Authorization-for-Simparica-Trio%C2%AE-sarolaner-moxidectin-and-pyrantel-chewable-tablets-for-Treatment-of-New-World-Screwworm-Infestations-in-Dogs-and-Puppies/)
- [Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs](https://www.reuters.com/legal/litigation/zoetis-gets-us-fda-emergency-use-nod-treatment-screwworm-dogs-2026-08-13/)
- [Zoetis (NYSE:ZTS) Hits New 1-Year Low on Analyst Downgrade](https://www.defenseworld.net/2026/08/11/zoetis-nysezts-hits-new-1-year-low-on-analyst-downgrade.html)
- [Zoetis Q2 Earnings Call Highlights](https://www.defenseworld.net/2026/08/11/zoetis-q2-earnings-call-highlights.html)

Zoetis has also been the In the Sweet Spot pick on: [July 9, 2026](/sweet-spot/zts-zoetis-2026-07-09).

## About In the Sweet Spot

Manifest Investing's daily stock pick: one high-quality company whose projected annual return (PAR) sits in the sweet spot above the market median (MIPAR). Each pick pairs Manifest Investing's quality percentile with its projected annual return (PAR); the sweet spot runs from MIPAR + 5 to MIPAR + 10 percentage points. Browse [every pick in the archive](/sweet-spot/archive).

_In the Sweet Spot is educational and is not investment advice or a recommendation to buy or sell any security. Figures reflect Manifest Investing's methodology as of the pick date._